Clene(us:CLNN)

2.85

-2.06%

Updated on 2025-05-06

Open:2.92
Close:2.85
High:2.93
Low:2.80
Prev Close:2.91
Volume:20672.00
Turnover:58868.00
Turnover Ratio:0.23%
Shares:8.98M
MarketCap:25.60M
DateTotalTotal SharesTotal RatioNewIncreasedDecreased
2024-06-30453376880.26%31217
2024-03-315272932925.68%7817
2023-12-3156116337149.06%101018
2023-09-30542463282819.18%51516
2023-06-30533228932425.15%2177
2023-03-314030341333.89%6815
2022-12-314530817184.12%9818
2022-09-305343280416.81%11828
dateorgNametotalratiochangeShareschangeRatio
2024-03-31Vanguard Group Inc26197032.04%13150.05%
2024-03-31Geode Capital Management, Llc9465320.74%33465354.69%
2024-03-31Lunt Capital Management, Inc.5128630.40%0
2024-03-31Scoggin Management Lp5000000.39%-250000-33.33%
2024-03-31Alyeska Investment Group, L.P.4741300.37%-1212760-71.89%
2024-03-31Morgan Stanley3386350.26%0
2024-03-31Laird Norton Wetherby Trust Company, Llc2685810.21%0
2024-03-31Citadel Advisors Llc2352410.18%-46098-16.39%
2024-03-31Blackrock Inc.1800090.14%-284209-61.22%
2024-03-31Northern Trust Corp1692250.13%37262.25%

About

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.
Address:6550 South Millrock Drive,Suite G50

Market Movers